Fredun Pharmaceuticals Limited
₹1,431.90▼ -45.15 (-3.06%)
FREDUN·BSE·Healthcare
Market Cap
2365.03 Cr
PE Ratio
21.43
Volume
8,650
Day High - Low
1479.75 - 1417.50
52W High-Low
1665.00 - 1195.20
₹1,431.90▼ -45.15 (-3.06%)
Market Cap2365.03 Cr
PE Ratio21.43
Volume8,650
Day High - Low1479.75 - 1417.50
52W High-Low1665.00 - 1195.20
Fredun Pharmaceuticals Limited (FREDUN): company summary
Fredun Pharmaceuticals has seen strong growth, with annual revenue rising 40.2% and net profit increasing 65.2% year-over-year.
Fredun Pharmaceuticals Limited (FREDUN) is a micro-cap Healthcare company valued at ₹2,365 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Fredun Pharmaceuticals Limited last traded at ₹1,431.9, down 3.06% on the day.
- Recent developments
- On 2026-09-22, Fredun Pharmaceuticals acquired a 26% stake in Goodman Vetcare Private Limited to create an integrated pet-health platform in India. On 2026-08-05, the company's stock surged following a 94% year-over-year rise in quarterly net profit to ₹13 crore.
- Financial performance
- Fredun Pharmaceuticals has seen strong growth, with annual revenue rising 40.2% and net profit increasing 65.2% year-over-year. The latest quarter showed even sharper growth, with revenue and net profit rising 90.8% and 93.9% respectively compared to the same quarter a year earlier. The net profit margin improved by 0.8 percentage points to 5.2%, while return on equity and return on capital employed remained at 11.7% and 17.2% respectively.
- Valuation multiples
- The stock trades at 21.4 times earnings, a discount to the Healthcare median of 32.0, 2.67 times book value. It yields 0.1%.
- Things to watch
- The stock is 11.2% below its 52-week high, and the company's market cap is ₹2,443 crore, classifying it as a micro-cap. While the business has grown significantly, the net profit margin remains relatively low at 5.2%, and the debt-to-equity ratio stands at 0.80, indicating moderate leverage.
- Where it stands
- Fredun Pharmaceuticals has delivered robust revenue and profit growth, with the latest quarter showing the highest increases. The company's market cap remains low, and its stock is trading below its 52-week high. The most significant movement was in the latest quarter net profit, which rose 93.9% year-over-year.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
5.9/10
Fair
Fair Value
Sign in to see
ROE
11.73%
Average
P/E
21.43x
Fair
Debt / Equity
0.80
Moderate
Industry
Healthcare
Pharmaceuticals
Overall View
Fair
Price performance
Day₹1418
₹1480
52W₹1195
₹1665
DocStoX take
Supported by growth (10.0) and risk (6.3), but held back by valuation (3.6).
DocStoX score
Low confidence5.9
/10
Fair
Quality
Modest
ROE 11.7%
Valuation
Rich
P/E 21.4×
Growth
Strong
Revenue +36.4% 5Y CAGR
Risk
Moderate
D/E 0.80
Momentum
Firm
50% of 52-week range
At a glance
Market Cap
₹2,365 Cr
52W High / Low
₹1665 / ₹1195
Dividend Yield
0.05%
Promoter Holding
44.57%
EPS (TTM)
₹66.81
Book Value
₹508.17
Key highlights
- Profit compounding 75% a year
- Revenue compounding 36% a year
- Profitable in all of the last 5 years
3 Positives0 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Fredun Pharmaceuticals Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Fredun Pharmaceuticals Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedLaurus Labs LimitedZydus Lifesciences LimitedApollo Hospitals Enterprise LimitedCipla LimitedDr. Reddy's Laboratories LimitedMankind Pharma LimitedAurobindo Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Fredun Pharmaceuticals Limited with peers
Fredun Pharmaceuticals Limited vs Sun Pharmaceutical Industries LimitedFredun Pharmaceuticals Limited vs Divi's Laboratories LimitedFredun Pharmaceuticals Limited vs Torrent Pharmaceuticals LimitedFredun Pharmaceuticals Limited vs Laurus Labs LimitedFredun Pharmaceuticals Limited vs Zydus Lifesciences LimitedFredun Pharmaceuticals Limited vs Apollo Hospitals Enterprise Limited
Related tools & concepts
Value Fredun Pharmaceuticals Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing